For research and educational purposes only. Not medical advice.
Cerebrolysin Reference
Educational, not medical advice reference for Cerebrolysin: Cognitive, Longevity; regulatory status, evidence posture, source review, and schedu…
Reference summary
Published randomized human trial literature exists primarily in acute ischemic stroke and vascular dementia, with meta-analyses reporting mixed but generally positive effect sizes. Trial quality and generalizability beyond acute-stroke settings remain debated.
Regulatory and posture
- Categories
- Cognitive, Longevity
- Aliases
- Porcine-brain peptide mixture, FPF-1070
- Evidence posture
- translational - Approved in several non-US markets but not FDA-approved. Trial quality and generalizability beyond acute-stroke settings are debated; long-term cognitive-enhancement use is not supported by the trial base. No validated subcutaneous community protocol exists.
- Regulatory status
- No FDA-approved Cerebrolysin drug label. Cerebrolysin is a porcine-brain-derived neuropeptide mixture approved in several non-US markets (including parts of Europe, Asia, and the former Soviet states) for stroke, traumatic brain injury, and dementia indications; it is not FDA-approved.
- Content review status
- research reference
Selected public sources
Related tools
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.
- Protocol builder overview - Public overview of the Pro protocol builder.